Begin typing your search above and press return to search.
Hyd-based Pharma Company applies for emergency use of Aviptadil Drug with DCGI
By: Tupaki Desk | 12 Jun 2021 7:58 AM GMT
After Bharat Biotech, one more Pharma company is all set to play a big role in helping India to beat the ongoing Coronavirus pandemic, which had left around three crore people infected with the respiratory disease.
Hyderabad-based Biophore India Pharmaceuticals has applied for emergency-use approval for Aviptadil drug with the Drugs Controller General of India (DCGI). The pharma company said the drug can be used to treat moderate to severe patients of Covid.
The Pharma company applied for the emergency use authorisation on Friday and the production of the drug for commercial purposes will commence, once the DGCI gives its nod for the product.
The data of clinical trials of the Aviptadil was also submitted to the DGCI. The vaccine was administered to Covid-19 patients across the globe with respiratory issues. The outcome of the study is satisfactory, the Hyd-based pharma company said.
Biophore CEO Jagadeesh Babu Rangisetty said that the clinical studies stated that patients administered with Aviptadil displayed a high recovery rate. We are hopeful of getting the approval.
The Hyd-based pharma company is among the pharma companies that have got the approvals to manufacture Favipiravir, an antiviral agent, last year, during the Coivid first wave period.
Hyderabad-based Biophore India Pharmaceuticals has applied for emergency-use approval for Aviptadil drug with the Drugs Controller General of India (DCGI). The pharma company said the drug can be used to treat moderate to severe patients of Covid.
The Pharma company applied for the emergency use authorisation on Friday and the production of the drug for commercial purposes will commence, once the DGCI gives its nod for the product.
The data of clinical trials of the Aviptadil was also submitted to the DGCI. The vaccine was administered to Covid-19 patients across the globe with respiratory issues. The outcome of the study is satisfactory, the Hyd-based pharma company said.
Biophore CEO Jagadeesh Babu Rangisetty said that the clinical studies stated that patients administered with Aviptadil displayed a high recovery rate. We are hopeful of getting the approval.
The Hyd-based pharma company is among the pharma companies that have got the approvals to manufacture Favipiravir, an antiviral agent, last year, during the Coivid first wave period.
